Juergen Rapp, a distinguished R&D staff scientist in ORNL’s Fusion Energy Division in the Nuclear Science and Engineering Directorate, has been named a fellow of the American Nuclear Society
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
In the 1960s, Oak Ridge National Laboratory's four-year Molten Salt Reactor Experiment tested the viability of liquid fuel reactors for commercial power generation. Results from that historic experiment recently became the basis for the first-ever molten salt reactor benchmark.
As scientists study approaches to best sustain a fusion reactor, a team led by Oak Ridge National Laboratory investigated injecting shattered argon pellets into a super-hot plasma, when needed, to protect the reactor’s interior wall from high-energy runaway electrons.
The Department of Energy’s Oak Ridge National Laboratory is collaborating with industry on six new projects focused on advancing commercial nuclear energy technologies that offer potential improvements to current nuclear reactors and move new reactor designs closer to deployment.
Experts focused on the future of nuclear technology will gather at Oak Ridge National Laboratory for the fourth annual Molten Salt Reactor Workshop on October 3–4.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.